Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-PDAC-288 in first-line metastatic pancreatic ductal adenocarcinoma
CTR20262376Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of telisotuzumab adizutecan, fluorouracil, folinic acid, oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by AbbVie Inc.. Started May 2026; status: active.
02
Drugs
telisotuzumab adizutecanfluorouracilfolinic acidoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20262376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262376.